The quality of evidence is downgraded by study limitations (unclear allocation concealment and lack of blinding) and by imprecise results (few patients and outcome events and wide confidence intervals).
A Cochrane review [Abstract] 1 included 1 study with a total of 102 subjects. There was no association between the addition of ASA to IVIG treatment on the rate of coronary artery abnormalities at follow up: prior to 30 days from onset of symptoms (RR 0.97, 95% CI 0.43 to 2.19) or at 30 days post onset of symptoms (RR 1.30, 95% CI 0.37 to 4.56).
Clinical comment: Current guidelines recommend the use of aspirin in Kawasaki disease. The American Heart Association 2 guideline states that administration of moderate- (30-50 mg/kg/day) to high-dose (80-100 mg/kg/day) aspirin is reasonable until the patient is afebrile, although there is no evidence that it reduces coronary artery aneurysms.
Primary/Secondary Keywords